gastro-congress-2018-posters-abstracts

21 / 21

Page 94
conferenceseries.com
Volume 8 Journal of Gastrointestinal & Digestive System
ISSN: 2161-069X Gastro Congress 2018
August 20-21, 2018
August 20-21, 2018 | Rome, Italy
13th Euro-Global
Gastroenterology Conference
Febuxostat versus placebo or allopurinol for gout or asymptomatic hyperuricemia: A systematic
review and meta-analysis
Sami Salahia1, Hamed Ellotf2, Mohammed Shehata3, Wafa Khoudeir1, Ibraheem Sabbagh1, Muhammed Sinokrot4, Mohamed Mamdouh 5, Hamza
Ibrahim5, Mohamed Abdelmongy6, Mohamed Omar Herdan7, Isaac Ibrahim2, Ahmed M Afif1 and Ahmed Elgebaly2
1Ain Shams University, Egypt
2Al Azhar University, Egypt
3Zagazig University, Egypt
4Cairo University, Egypt
5Alexandria University, Egypt
6MISR University for Science & Technology, Egypt
7Assiut University, Egypt
Background/Introduction: Gout is one of the most common rheumatic diseases in humans characterized by increased serum
uric acid level) above of 7 mg/dl in men and 5.7 in women while deposition of uric acid crystals in the joints. Urate lowering
therapy (ULT) is the novel treatment for patients with gout. There is an ongoing debate about using which of the urate lowering
therapies should be preferred
Aim: The aim of this study is to systemically review the literature and statistically analyze the safety and efficacy outcomes of
febuxostat versus allopurinol in the treatment of gout or asymptomatic hyperuricemia.
Methodology: We searched 12 electronic medical databases and included randomized clinical trials (RCTs) comparing clinical
outcomes between febuxostat and allopurinol in patients with gout or asymptomatic hyperuricemia.
Results: Nine RCTs were included in our meta-analysis. Febuxostat had significantly higher incidence of serum urate at last 3
monthly visits (RR=2.26, 95% CI [1.82, 2.80], p<0.00001) and at last visit (RR=1.81, 95% CI [1.65, 1.98], p<0.00001) compared
to allopurinol. Mean change frombaseline of serumurate <6.0mg/dl at last 3monthly visits was significantly lower in febuxostat
than allopurinol (SDM=-0.84, 95% CI [-1.14, -0.55], p<0.00001). While, regarding serum urate <360 mg/dl at last 3 monthly
visits, mean change from baseline did not favor any of the compared groups. No significant difference was detected between
febuxostat and allopurinol in terms of safety outcomes such as, any adverse events, treatment related adverse event, events
leading to discontinuation, serious adverse events, liver or renal function test abnormalities, abnormal electrocardiograph,
abnormal urine protein or glucose, headache, upper respiratory infection, or gastrointestinal disorders.
Conclusions: Based on our study, febuxostat showed higher incidence of serum urate at last three-monthly visits and last visit
than allopurinol. While, febuxostat and allopurinol were comparable in terms of safety outcomes.
J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C5-077